UAE – Swiss biotechnology company Rejuveron has completed a US$75M series B financing round with a significant investment from Mubadala, an investment firm headquartered in Abu Dhabi.
Rejuveron is a fully integrated biotechnology platform company that invests in people and ideas to develop therapies and technologies in order to promote healthy aging and prolong lifespan.
The European company provides start-up coaching and funding to entrepreneurial scientists to co-create therapies that benefit aging populations worldwide.
In a press release published by Bloomberg, Christian Angermayer, Co-Founder and Chairman of the Board of Directors at Rejuveron, said: “Rejuveron has a closed US$75 million financing round with Mubadala joining the syndicate.”
Rejuveron has secured around US$75 million from a series B funding round, which drew support from Mubadala’s asset management unit Mubadala Capital.
This financial decision comes shortly after Mubadala committed US$1 billion to Blue Owl Capital’s credit platform, an alternative investment manager with US$150 billion in assets under management.
Moreover, the new investment round was co-led led by Catalio Capital Management and Apeiron Investment Group, the private investment company of German businessman Christian Angermayer.
Rejuveron has raised a total capital of US$75 million at a valuation of nearly US$400 million, signaling a continued growing investor interest in life science and biotech companies at all stages of development.
Sharing his insights, Christian Angermayer stated: “With this latest funding, Rejuveron will continue its mission to develop therapies that could extend life expectancy significantly.”
The latest investment in Rejuveron serves as a testament to the potential of the company’s mission to develop therapies that promote healthy aging and extend people’s longevity.
Moreover, the new capital injection comes as the Middle East and North Africa region is witnessing several major announcements to propel longevity research and development.
The new round of investment will help Rejuveron not only accelerate its global expansion strategies but also bolster business growth in the Middle Eastern region.
The Swiss biotechnology company is gearing up to open an office in the Emirate of Abu Dhabi, in alignment with its expansion strategy in the Middle East.
Rejuveron will use part of the fresh funds to speed up product development as well as create therapies and technologies that seek to combat aging.
These strategic moves are expected to contribute to the outlined objectives of the United Arab Emirates, the Kingdom of Saudi Arabia, and countries of the Gulf Cooperation Council to advance a healthcare system that encompasses longevity and preventive medicine.
Laying out Rejuveron’s future ambitions, Angermayer noted: “We believe that taking our place in the thriving MENA ecosystem will help our development goals and invigorate healthcare delivery that is much needed to advance the cause of preventive medicine.”
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
